Ocean Biomedical, Inc.
OCEA evidence brief
What we can confirm
- Market Cap:
- $256K
What it means
What to watch
Prepared research question
What matters most for OCEA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCEA
Ocean Biomedical, Inc. (OCEA) is a clinical-stage biotechnology company that licenses and develops drug candidates from academic institutions, focusing on oncology, fibrosis, and infectious disease programs, and has not yet generated product revenue.
Key risk: No product revenue
Market Cap
$256K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2025.
Ocean Biomedical, Inc. (OCEA) is a clinical-stage biotechnology company that licenses and develops drug candidates from academic institutions, focusing on oncology, fibrosis, and infectious disease programs, and has not yet generated product revenue.
- Ocean Biomedical has not generated any revenue from product sales and has incurred significant operating losses since its inception in 2019 [sec_mda · as of 2025-05-15].
- The company reported a net loss of -$8.2M and negative shareholders' equity of -$92.4M as of 2025-03-31 [sec].
- Its pipeline includes clinical-stage programs, with plans to move certain preclinical candidates into the clinic within the next 12 to 24 months [sec_mda · as of 2025-05-15].
- The company's business model relies on licensing inventions from research universities, with current active assets licensed from Brown University and Rhode Island Hospital [sec_mda · as of 2025-05-15].
- Ocean Biomedical expects expenses to increase substantially as it advances preclinical activities and clinical trials, and it intends to raise additional capital through means such as public offerings [sec_mda · as of 2025-05-15].
What works
- The company has established partnerships with research institutions (Brown University and Rhode Island Hospital) to source breakthrough discoveries, providing a structured pipeline of innovations [sec_mda · as of 2025-05-15].
- Its multi-disciplinary leadership team includes physicians, scientists, and business leaders with relevant expertise to advance drug development [sec_mda · as of 2025-05-15].
- Ocean Biomedical employs a flexible commercialization strategy, assessing internal advancement, partnerships, and spin-outs to maximize each program's value [sec_mda · as of 2025-05-15].
What to weigh
- The company has no product revenue and has incurred significant operating losses since inception, with a net loss of -$8.2M and negative shareholders' equity of -$92.4M as of 2025-03-31 [sec].
- Ocean Biomedical faces substantial funding uncertainty; if unable to obtain additional capital, it may be forced to delay, reduce, or eliminate R&D programs [sec_mda · as of 2025-05-15].
- The successful development and commercialization of its product candidates is highly uncertain due to numerous risks, including preclinical and clinical trial costs, regulatory approvals, and market acceptance [sec_mda · as of 2024-11-25].
From the filings
Quoted directly from source documents.
The company has not generated any revenue from product sales.
“We have not generated any revenue from product sales.”
SEC MD&A · May 15, 2025
The company expects expenses to increase substantially as it advances preclinical and clinical activities.
“We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates.”
SEC MD&A · May 15, 2025
Current active assets are licensed from Brown University and Rhode Island Hospital.
“Our current active assets are licensed from Brown University and Rhode Island Hospital.”
SEC MD&A · November 25, 2024
Risks & what to watch (4)›
Key risks
- No product revenue — Company has not generated any revenue from product sales since inception in 2019 [sec_mda · as of 2025-05-15].
- Funding uncertainty — If unable to obtain funding, R&D programs may be delayed, reduced, or eliminated [sec_mda · as of 2025-05-15].
- Negative shareholders' equity — Shareholders' equity is -$92.4M as of 2025-03-31, indicating liabilities exceed assets [sec].
- Development and commercialization risk — Successful development and commercialization of product candidates is highly uncertain [sec_mda · as of 2024-11-25].
What to watch
- Ability to raise additional capital through public offerings or other means to fund ongoing operations and R&D [sec_mda · as of 2025-05-15].
- Progress of preclinical candidates moving into the clinic within the next 12 to 24 months [sec_mda · as of 2025-05-15].
- Any updates on partnerships or licensing agreements with research institutions that could expand the pipeline [sec_mda · as of 2025-05-15].
- Financial reports for changes in net loss, cash position, and shareholders' equity [sec].
Sources: SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Ocean Biomedical, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ocean Biomedical, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| fny investment advisers, llc | 600 | $0 |
Short Interest
as of May 21, 2026- % of float
- 2.0%
- Days to cover
- 0.1
- Shares short
- 2,930,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCEA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ocean Biomedical, Inc.?
Ocean Biomedical, Inc. (OCEA) is a clinical-stage biotechnology company that licenses and develops drug candidates from academic institutions, focusing on oncology, fibrosis, and infectious disease programs, and has not yet generated product revenue.
Who is the CEO of Ocean Biomedical, Inc.?
Michelle Berrey, M.D. is the chief executive officer of Ocean Biomedical, Inc. (OCEA).
Where is Ocean Biomedical, Inc. headquartered?
Ocean Biomedical, Inc. (OCEA) is headquartered in Providence, RI, United States.
What therapeutic areas does Ocean Biomedical, Inc. focus on?
Ocean Biomedical, Inc. develops therapies across Oncology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.